NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free SANA Stock Alerts $7.73 -0.53 (-6.42%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$7.64▼$8.2050-Day Range$6.16▼$11.2752-Week Range$2.74▼$12.00Volume1.88 million shsAverage Volume3.10 million shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice Target$11.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Sana Biotechnology alerts: Email Address Sana Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside50.9% Upside$11.67 Price TargetShort InterestBearish22.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$10 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.02) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.73 out of 5 starsMedical Sector622nd out of 919 stocksBiological Products, Except Diagnostic Industry105th out of 151 stocks 3.4 Analyst's Opinion Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSana Biotechnology has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.16% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Sana Biotechnology has recently increased by 5.88%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SANA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Sana Biotechnology this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,999,996.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders34.90% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($1.02) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Sana Biotechnology Stock (NASDAQ:SANA)Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Read More SANA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SANA Stock News HeadlinesMarch 17, 2024 | seekingalpha.comSana Biotechnology: Now In Overbought TerritoryMarch 16, 2024 | finance.yahoo.comSANA Apr 2024 15.000 callApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereMarch 14, 2024 | finance.yahoo.comJ&J, Novo support Asgard’s push to make ‘in vivo’ cell therapiesMarch 11, 2024 | finance.yahoo.comDirector Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)March 7, 2024 | finance.yahoo.comBaillie Gifford Bolsters Stake in Sana Biotechnology IncMarch 1, 2024 | markets.businessinsider.comSana Biotechnology: Buy Rating Affirmed Amid Anticipation of Clinical Breakthroughs and Hypoimmune Platform ValidationMarch 1, 2024 | markets.businessinsider.comSana Biotechnology: Promising Clinical Prospects and Buy Rating Justified by Upcoming Data ReadoutsApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereMarch 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA) and Sana Biotechnology (SANA)February 29, 2024 | globenewswire.comSana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesFebruary 28, 2024 | globenewswire.comSana Biotechnology to Present at the Cowen 44th Annual Health Care ConferenceFebruary 19, 2024 | finance.yahoo.comInstitutional investors are Sana Biotechnology, Inc.'s (NASDAQ:SANA) biggest bettors and were rewarded after last week's US$521m market cap gainFebruary 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 13, 2024 | finance.yahoo.comSana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHPFebruary 12, 2024 | finance.yahoo.comSana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesFebruary 9, 2024 | msn.comSana Biotechnology Announces Pricing of Upcoming OfferingFebruary 9, 2024 | msn.comSana Biotechnology’s Major Public Offering AgreementFebruary 8, 2024 | bizjournals.comSana Biotechnology raising $165M through public offeringFebruary 8, 2024 | msn.comSana Biotechnology Previews Preliminary Financials and Trial ProgressFebruary 8, 2024 | msn.comSana Biotechnology down 5%, prices $165M offeringFebruary 8, 2024 | markets.businessinsider.comSana Biotechnology Prices Upsized Public Offering Of $165 Mln Of SharesFebruary 8, 2024 | finance.yahoo.comSana Biotechnology Announces Pricing of Upsized Public OfferingFebruary 7, 2024 | marketwatch.comSana Biotechnology Shares Fall After Public Offering NewsFebruary 7, 2024 | finance.yahoo.comSana Biotechnology Announces Proposed Public Offering of Common StockFebruary 1, 2024 | benzinga.comSana Biotechnology Stock (NASDAQ:SANA) Dividends: History, Yield and DatesJanuary 28, 2024 | finance.yahoo.comBaillie Gifford Reduces Stake in Sana Biotechnology IncSee More Headlines Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/18/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SANA CUSIPN/A CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees328Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$15.00 Low Stock Price Target$8.00 Potential Upside/Downside+49.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-283,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.36% Return on Assets-47.89% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book5.34Miscellaneous Outstanding Shares220,450,000Free Float143,512,000Market Cap$1.72 billion OptionableOptionable Beta1.61 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Steven D. Harr M.D. (Age 54)President, CEO & Director Comp: $1.04MMr. Bernard J. Cassidy J.D. (Age 69)Executive VP, General Counsel & Corporate Secretary Comp: $491.39kMr. Nathan Hardy M.B.A. (Age 48)Executive VP & CFO Comp: $683.49kDr. Edward Rebar Ph.D. (Age 56)Senior VP & CTO Ms. Robin Andrulevich (Age 58)Executive VP & Chief People Officer Mr. Paul Brunetta M.D.Senior VP and Head of Clinical & Translational ScienceMr. Christian Hordo M.B.A. (Age 41)Executive VP & Chief Business Officer Comp: $485.03kDr. Sonja Schrepfer M.D. (Age 49)Ph.D., Senior VP & Head of Hypoimmune Platform Dr. Terry Fry M.D. (Age 57)Senior VP & Head of T Cell Therapeutics Dr. Steven A. Goldman M.D. (Age 66)Ph.D., Senior VP & Head of CNS Therapy More ExecutivesKey CompetitorsFusion PharmaceuticalsNASDAQ:FUSNRecursion PharmaceuticalsNASDAQ:RXRXAmbrx BiopharmaNYSE:AMAMNeumora TherapeuticsNASDAQ:NMRAGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsLos Angeles Capital Management LLCSold 64,393 shares on 4/5/2024Ownership: 0.032%Vanguard Group Inc.Bought 629,499 shares on 3/11/2024Ownership: 4.444%Goldman Sachs Group Inc.Bought 215,650 shares on 3/1/2024Ownership: 0.421%American International Group Inc.Bought 1,151 shares on 2/28/2024Ownership: 0.024%Virtu Financial LLCBought 6,921 shares on 2/26/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions SANA Stock Analysis - Frequently Asked Questions Should I buy or sell Sana Biotechnology stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SANA shares. View SANA analyst ratings or view top-rated stocks. What is Sana Biotechnology's stock price target for 2024? 4 Wall Street research analysts have issued 1 year price objectives for Sana Biotechnology's shares. Their SANA share price targets range from $8.00 to $15.00. On average, they predict the company's share price to reach $11.67 in the next year. This suggests a possible upside of 50.9% from the stock's current price. View analysts price targets for SANA or view top-rated stocks among Wall Street analysts. How have SANA shares performed in 2024? Sana Biotechnology's stock was trading at $4.08 at the start of the year. Since then, SANA stock has increased by 89.5% and is now trading at $7.73. View the best growth stocks for 2024 here. When is Sana Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SANA earnings forecast. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) announced its earnings results on Thursday, February, 29th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03. During the same period in the prior year, the firm posted ($0.40) EPS. What ETFs hold Sana Biotechnology's stock? ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares Genomics Immunology and Healthcare ETF (IDNA).IQ Chaikin U.S. Small Cap ETF (CSML). When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $322 million in an initial public offering on Thursday, February 4th 2021. The company issued 15,000,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO. Who are Sana Biotechnology's major shareholders? Sana Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.03%). Insiders that own company stock include Christian Hordo, James J Macdonald, Joshua H Bilenker, Patrick Y Yang, Robert Nelsen and Ventures Fund V Gener Flagship. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SANA) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchThe Next Nvidia?InvestorPlaceTop 5 AI Stocks to Buy for 2024Market Moving TrendsHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.